REMINDER: Our user survey closes on Friday, please submit your responses here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRentokil Initial Regulatory News (RTO)

Share Price Information for Rentokil Initial (RTO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 419.60
Bid: 419.50
Ask: 419.80
Change: 11.90 (2.92%)
Spread: 0.30 (0.072%)
Open: 417.60
High: 420.20
Low: 415.10
Prev. Close: 407.70
RTO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

3rd Quarter Trading Update

17 Oct 2019 07:00

RNS Number : 1461Q
Rentokil Initial PLC
17 October 2019
 

  

17 October 2019

RENTOKIL INITIAL PLC - THIRD QUARTER TRADING UPDATE

 

Another strong quarter: Ongoing Organic Revenue growth of 5.5% our highest level in over 10 years, continued progress in M&A, on track to meet expectations for the full year

 

 

(£m)

Q3 2019

Growth

AER

AER

CER

Ongoing Revenue1

723.0

13.6%

9.8%

Revenue

727.2

13.4%

9.6%

 

Overview (CER)

 

Ongoing Revenue increased by 9.8% in Q3, of which 5.5% was Organic2 (H1 2019: 4.2%, Q3 2018: 4.1%) and 4.3% was from acquisitions.

Ongoing revenue in Pest Control grew by 12.3% (5.9% Organic), with good performances delivered across both Growth and Emerging markets, which grew by 12.2% and 12.7% respectively. Our North American, UK & Rest of World and Latin American operations delivered particularly good growth in the period.

Our Hygiene business performed well during the quarter, with Ongoing Revenue increasing by 5.5%, and Organic Revenue rising by 4.8%. This reflects good growth in the UK, Europe and Pacific and the ongoing contribution from acquisitions.

Ongoing Revenue in our Protect & Enhance category grew by 4.9% (4.5% Organic), reflecting a solid performance from both France Workwear and Ambius, and an improved performance from our UK Property Care business which encouragingly delivered positive growth.

During the third quarter the Company undertook its biennial survey of our 40,000 colleagues around the world. 90% of our colleagues participated and the results continued to place Rentokil Initial in the global High Performance group of leading companies for both Colleague Engagement and Enablement.

M&A

​We acquired 15 businesses in the quarter across all of our regions (except Pacific), with annualised revenues of c. £15m. 12 Pest Control businesses were acquired, predominantly in North America and Latin America. For the year to 30 September 2019 we have acquired a total of 32 businesses (24 in Pest Control, five in Hygiene and three in Protect & Enhance) primarily in Emerging and Growth markets. Annualised revenues of the businesses acquired so far in 2019 totalled c. £70m in the year prior to purchase. Our M&A pipeline going into Q4 and 2020 remains strong.

Conclusion of CMA reviews

 

The CMA's reviews into the acquisitions of Cannon UK and MPCL (formerly Mitie Pest) concluded on 30 September following completion of the partial divestments required on each by the CMA. Integration of the retained businesses is now proceeding at pace.

​Commenting on today's announcement Andy Ransom, Chief Executive, said:

"I am pleased with our Q3 results and our Group Organic Growth of 5.5% is our highest level of quarterly Organic Growth in over a decade. Pest Control has performed well, growing organically by 5.9%, and Hygiene has demonstrated further momentum, growing organically by 4.8%. Our performance in Q3, combined with further progress in our value-creating M&A programme, means we remain on track to meet expectations for the full year.

"I am also delighted to see the excellent results of our colleague survey. We continue to deliver world-class standards of colleague engagement and enablement, and we see this in turn resulting in outstanding service for our customers and higher levels of retention. I'd like to thank all of our colleagues for their ongoing commitment and determination to be the best at what we do."

 

 

Enquiries:

 

Investors / Analysts:

Katharine Rycroft

Rentokil Initial plc

07811 270734

Media:

Malcolm Padley

Rentokil Initial plc

07788 978 199

 

 

1Ongoing Revenue represents the performance of the continuing operations of the Group (including acquisitions) after removing the effect of disposed or closed businesses.

 

2Organic Revenue represents the growth in Ongoing Revenue excluding the effect of businesses acquired during the year. Acquired businesses are included in organic measures in the year following acquisition, and the comparative period is adjusted to include an estimated full year performance for growth calculations.

 

AER - actual exchange rates; CER - constant 2018 exchange rates

 

This announcement contains statements that are, or may be, forward-looking regarding the Group's financial position and results, business strategy, plans and objectives. Such statements involve risk and uncertainty because they relate to future events and circumstances and there are accordingly a number of factors which might cause actual results and performance to differ materially from those expressed or implied by such statements. Forward-looking statements speak only as of the date they are made and no representation or warranty, whether expressed or implied, is given in relation to them, including as to their completeness or accuracy or the basis on which they were prepared. Other than in accordance with the Company's legal or regulatory obligations (including under the Listing Rules and the Disclosure Guidance and Transparency Rules), the Company does not undertake any obligation to update or revise publicly any forward-looking statement, whether as a result of new information, future events or otherwise. Information contained in this announcement relating to the Company or its share price, or the yield on its shares, should not be relied upon as an indicator of future performance. Nothing in this announcement should be construed as a profit forecast.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTBLBDGUUBBGCL
Date   Source Headline
29th Jul 20217:00 amRNSInterim Results
8th Jul 20217:00 amRNSNotice of termination of guarantee
11th Jun 20211:50 pmRNSNotice of Early Redemption
12th May 20216:03 pmRNSResult of AGM
22nd Apr 20217:00 amRNSQ1 Trading Update
7th Apr 20212:01 pmRNSDirector/PDMR Shareholding
1st Apr 20216:30 pmRNSDirector/PDMR Shareholding
1st Apr 202110:23 amRNSBlock listing Interim Review
1st Apr 202110:16 amRNSChange of Registered Office
31st Mar 20214:00 pmRNSDirector/PDMR Shareholding
31st Mar 20211:16 pmRNSTotal Voting Rights
31st Mar 202110:33 amRNSAnnual Financial Report
30th Mar 20216:23 pmRNSDirector Declaration
24th Mar 20215:55 pmRNSDirector/PDMR Shareholding
12th Mar 20219:00 amRNSAdditional Listing
4th Mar 20217:05 amRNSDirectorate Change
4th Mar 20217:00 amRNSFinal Results
17th Feb 20215:45 pmRNSDirector Declaration
8th Jan 20217:00 amRNSQ4 2020 Acquisitions and Trading Update
27th Nov 20202:25 pmBUSEarly Repurchase(s)
27th Nov 20202:22 pmBUSEarly Repurchase(s)
24th Nov 20205:25 pmRNSDirector/PDMR Shareholding
20th Nov 20207:00 amRNSResult of Tender Offer for Notes due 2021
12th Nov 20209:02 amRNSTender Offer for Notes due 2021
22nd Oct 20207:00 amRNSQ3 Trading Update
8th Oct 20207:00 amRNSSuccessful EUR600m 8-year bond transaction priced
1st Oct 20209:00 amRNSBlock listing Interim Review
28th Aug 20203:40 pmRNSDirector/PDMR Shareholding
7th Aug 20205:24 pmRNSDirector/PDMR Shareholding
30th Jul 20207:00 amRNSInterim Results
6th Jul 20207:00 amRNSDirectorate Change
21st May 202011:00 amRNSDirector/PDMR Shareholding
13th May 20205:15 pmRNSResult of AGM
7th May 20204:45 pmRNSDirector/PDMR Shareholding
27th Apr 20203:50 pmRNSDisclosure of Rights Attached to Equity Shares
17th Apr 202011:59 amRNSDirector/PDMR Shareholding
16th Apr 20207:00 amRNSQ1 Trading Update
14th Apr 20205:26 pmRNSHolding(s) in Company
9th Apr 20204:35 pmRNSDirector/PDMR Shareholding
2nd Apr 20201:36 pmRNSDirector/PDMR Shareholding
1st Apr 20205:33 pmRNSConfirmation of Non-Executive Director Appointment
1st Apr 20209:24 amRNSBlock listing Interim Review
31st Mar 20202:18 pmRNSTotal Voting Rights
30th Mar 202012:37 pmRNSRedemption of 4.5% debenture stock
30th Mar 202012:24 pmRNSRedemption of 5% debenture stock
27th Mar 202011:00 amRNSHolding(s) in Company
26th Mar 20204:41 pmRNSSecond Price Monitoring Extn
26th Mar 20204:36 pmRNSPrice Monitoring Extension
26th Mar 202011:29 amRNSAnnual Financial Report
25th Mar 20207:00 amRNSTrading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.